DHANUKA AGRITECH LTD.

Dhanuka Agritech Limited has announced the launch of two new products: 'Wetcit Neo', a novel spray adjuvant, and 'Fujita', a systemic fungicide. Wetcit Neo is formulated with avocado oil, blackcurrant oil, and surfactants to enhance pesticide efficacy by improving spray spreading and absorption. Fujita contains Isoprothiolane 40% EC and is designed for effective control of rice blast, offering both preventive and curative action. Both products are currently targeted for the domestic Indian market.

Dhanuka Agritech Ltd has announced the closure of its trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from October 1, 2026, until 48 hours after the declaration of the un-audited financial results for the quarter and half-year ending September 30, 2026. This restriction applies to all designated persons and individuals possessing unpublished price-sensitive information, preventing them from trading in the company's shares during this period. The date of the board meeting to approve these financial results will be communicated separately.

Dhanuka Agritech Ltd has announced the launch of its new fungicide, POLIN (20% SC). Developed in collaboration with Nippon-Soda, Japan, this fungicide features a novel DHODHI mode of action (FRAC 52). POLIN offers preventive protection against Leaf & Neck Blast with translaminar and systemic action, ensuring extended crop protection. The product is targeted for the domestic Indian market.

Dhanuka Agritech Limited has announced the incorporation of its wholly owned subsidiary, Dhanuka Agritech Europe Private Limited, in Ireland. This new entity, established under Irish law, will focus on agrochemical business activities and related ventures. The incorporation was approved by the Companies Registration Office (CRO) in Ireland. Dhanuka Agritech has subscribed to 100 ordinary shares of EUR 1 each for a total consideration of EUR 100, acquiring 100% of the share capital. The subsidiary has not yet commenced business operations and therefore has a turnover of Nil.

Dhanuka Agritech Ltd has announced the appointment of Mr. Shalinder Singh as Senior Management Personnel, designated as General Manager- Sales. This appointment is effective from August 3rd, 2026. Mr. Singh brings over 20 years of experience in Sales and Marketing within the Agro-Inputs sector, with a strong background in various geographies and leadership roles at companies like Syngenta and Nagarjuna. He holds a Master of Science in Horticulture from Punjab Agriculture University. This move is expected to bolster the company's sales and marketing strategies.

Dhanuka Agritech Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors also approved an investment of up to ₹200 Crore for a new pesticide manufacturing unit in Nagpur, Maharashtra. Additionally, the company will grant a loan of up to ₹15 Crore to the Dhanuka Employee Stock Benefits Trust for its Stock Appreciation Rights Plan, 2026.

Dhanuka Agritech Ltd's Board of Directors has approved granting a loan of up to ₹15 Crore to the proposed Dhanuka Employee Stock Benefits Trust. This fund will be used for the implementation of the Dhanuka Stock Appreciation Rights Plan, 2026 (SAR 2026). The loan will be disbursed in one or more tranches and is intended for the acquisition of equity shares from the open market and administration of the SAR 2026 plan, in compliance with SEBI regulations. The board meeting also reviewed un-audited financial results for the quarter ended June 30, 2026, and approved an investment of up to ₹200 Crore for a new pesticide manufacturing unit in Nagpur, Maharashtra.

Dhanuka Agritech Ltd announced its Board of Directors has approved an investment of up to ₹200 Crore for establishing a new pesticide manufacturing unit in Nagpur, Maharashtra. The company also approved the un-audited financial results for the quarter ended June 30, 2026, and a loan of up to ₹15 Crore to the Dhanuka Employee Stock Benefits Trust for its "Dhanuka Stock Appreciation Rights Plan, 2026". The board meeting concluded on August 3, 2026.

Dhanuka Agritech opened FY27 with a weak, demand-led print: standalone revenue fell 12.6% YoY to ₹461.9 Cr and net profit dropped 34.6% YoY to ₹36.3 Cr (EPS ₹8.06 vs ₹12.31). This badly misses street and management's own set-up — Uniresearch had pencilled in ₹564 Cr revenue (+6.9%) and ₹64 Cr PAT (+14.3%), and on the Q1 FY26 concall management had guided to low-double-digit FY27 revenue growth on the full-year impact of acquired Bayer products and re-introduced biostimulants. Q1 delivered the opposite of that guidance on the topline, with the agri-input cyclicality management always flags (monsoon, pest, crop patterns) working against it this quarter. The damage is operating deleverage, not a one-off: with no exceptional items on either side, the profit fall is genuine. Net margin compressed to 7.9% from 10.5% a year ago, and EBIT-level margin thinned as expenses (₹422.2 Cr) fell far less than revenue — employee cost (₹46.5 Cr) and other expenses (₹60.9 Cr) were essentially flat YoY against a shrunken topline, while other income of ₹8.9 Cr and lower finance cost cushioned only marginally. The sequential optics are worse still (PAT ₹36.3 Cr vs ₹97.8 Cr in Q4) but that is a seasonality artifact — Q4 is Dhanuka's strong rabi quarter and is not the right comparison; YoY is the clean read here. The board paired the soft result with two capital moves signalling continued confidence in the runway: approval of up to ₹200 Cr for a new 23,000 MT/annum pesticide plant at Nagpur (operational by Mar/Apr 2028, funded by internal accruals/debt) to shorten lead times into South, East and Central India, and a ₹15 Cr loan to the employee trust for the SAR 2026 plan — on top of the ₹70 Cr buyback executed during the quarter. Q2 (kharif) will test whether the guided low-double-digit growth and Bayer/biostimulant contribution actually materialise, or whether the FY27 outlook needs to be reset lower.

Dhanuka Agritech Ltd has issued a clarification regarding the determination of the appreciation amount under its proposed Dhanuka Stock Appreciation Rights Plan, 2026 (SAR 2026). This clarification addresses queries from proxy advisory firms. The appreciation amount for each exercised SAR will be the cash equivalent of the increase in the underlying equity share's value. The calculation is defined as (Fair Market Value on Exercise Date – Exercise Price) × Number of SARs Exercised. The exercise price will be no less than the closing market price on the grant date, considering higher trading volumes on that day. The company has also made this information available on its website.